Ozempic (semaglutide injection) is a GLP-1 receptor agonist marketed by Novo Nordisk. It is FDA-approved for three indications in adults: improving glycemic control in type 2 diabetes, reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (approved January 2025). These indications are supported by the SUSTAIN, PIONEER, and FLOW trial programs.
Coverage is broadly available: PrescriberPoint data indicate Ozempic is on formulary for more than 80% of commercial plans. However, 100% of plans require prior authorization, and coverage is restricted to FDA-approved indications. Off-label prescribing for weight loss is a common reason for denial.
This guide explains the coverage structure, prior authorization requirements, cost-sharing, and savings programs that access teams and prescribers need to understand.
Who this is for
Pharmacy access teams, managed care liaisons, prior authorization coordinators, and healthcare providers who prescribe Ozempic and need to understand payer coverage, documentation requirements, and appeal pathways.
FDA-approved indications that drive coverage
Ozempic has four FDA-approved indications. Coverage hinges on the documented diagnosis matching an approved indication.
| Indication | Key trial | Approval year |
|---|---|---|
| Glycemic control in type 2 diabetes | SUSTAIN program | 2017 |
| MACE reduction in T2D with established CVD | SUSTAIN-6 | 2017 |
| Kidney disease and CV death risk reduction in T2D with CKD | FLOW | 2025 |
| (Note: chronic weight management is a Wegovy indication, not Ozempic) | — | — |
Prescribing Ozempic for weight management alone is off-label. Most commercial and all Medicare plans will deny coverage for off-label weight loss. The FDA-approved weight management product from the same molecule is Wegovy (semaglutide 2.4 mg injection or 25 mg tablet).
Commercial insurance coverage
Formulary placement
Ozempic is typically placed on specialty tiers (Tier 3 or Tier 4) of commercial formularies. It is covered by the majority of plans, but plan-specific tier placement determines the copay or coinsurance amount.
Typical commercial cost-sharing:
| Tier | Typical monthly copay | Notes |
|---|---|---|
| Preferred specialty (Tier 3) | $25–$75 | More common on plans with strong GLP-1 coverage |
| Non-preferred specialty (Tier 4) | $100–$150+ | Coinsurance may apply; percentage of list price |
With the Novo Nordisk Savings Card, commercially insured patients may pay as little as $25/month (subject to a maximum savings of $100/month). Government beneficiaries are excluded from the savings card.
Prior authorization
100% of plans require prior authorization for Ozempic. Typical PA criteria include:
- Confirmed diagnosis of type 2 diabetes — documented via ICD-10 code (E11.x), A1C results, or medical records.
- Step therapy — many plans require documented failure, contraindication, or intolerance of metformin and/or other first-line agents before approving a GLP-1.
- Cardiovascular or kidney indication documentation — for the MACE or CKD indications, plans may require records showing established CVD (prior MI, stroke, or symptomatic PAD) or confirmed CKD diagnosis.
- Quantity limits — most plans cover one pen per month (four weekly doses).
Incomplete documentation is the most common reason for PA denial. Access teams should ensure the PA submission includes the diagnosis code, relevant lab results (A1C, eGFR, UACR), medication history, and any contraindication notes for prior therapies.
Medicare Part D coverage
Medicare Part D covers Ozempic when prescribed for its FDA-approved diabetes and cardiovascular/kidney indications. It is not covered for weight loss under current CMS rules.
Key points for Medicare beneficiaries:
- Formulary: Ozempic is listed on most Part D formularies. Novo Nordisk reports that 98% of Part D beneficiaries have formulary coverage for Ozempic.
- Prior authorization: Required by most Part D plans. Documentation requirements mirror commercial PA criteria.
- Cost-sharing: Under the Inflation Reduction Act, the annual out-of-pocket cap for Part D prescriptions is $2,100 in 2026. Beneficiaries may face coinsurance of 25% before reaching the cap.
- 2026 PAP change: Novo Nordisk updated its Patient Assistance Program for 2026 to exclude most Medicare Part D patients, citing the widespread Part D formulary coverage. Medicare patients should verify their Part D plan covers Ozempic during open enrollment.
Medicaid coverage
Medicaid coverage for Ozempic varies by state:
| State category | Coverage status |
|---|---|
| Covers Ozempic for T2D with PA | Most states; includes California, New York, Texas, Florida |
| Covers with strict PA criteria | Some states require step therapy, documented BMI, and prior therapy failure |
| Weight loss coverage | Most state Medicaid programs do not cover GLP-1s for weight loss; some (California, New York) have restricted coverage |
Patients and providers should verify coverage through their state Medicaid formulary or managed care organization's preferred drug list.
Savings and assistance programs
| Program | Monthly cost | Eligibility |
|---|---|---|
| NovoCare Savings Card (commercial) | As little as $25/month | Commercial insurance; not available for government beneficiaries |
| NovoCare Pharmacy self-pay | $199/month (0.25 mg, 0.5 mg intro offer through June 2026), then $349/month (0.25–1 mg), $499/month (2 mg) | Uninsured or cash-pay patients |
| Novo Nordisk Patient Assistance Program | Free | Uninsured patients at or below 200% of FPL; Medicare Part D patients excluded as of 2026 |
The savings card can be activated by texting SAVE to 83757 or visiting Ozempic.com/savings.
Major payer-specific coverage patterns
Coverage varies significantly by insurer. The following reflects publicly available data as of May 2026.
| Insurer | Typical Ozempic coverage | Key requirements |
|---|---|---|
| Aetna (commercial) | Covered for T2D; preferred brand tier | PA required; quantity limits; BMI documentation needed for weight management |
| Blue Cross Blue Shield | Varies by state affiliate; diabetes coverage more consistent | PA frequently required; step therapy may apply |
| Cigna | Available for T2D | PA and quantity limits common; prior lifestyle intervention documentation |
| Humana | Available on many formularies for diabetes | PA and quantity limits; prior documentation of lifestyle intervention |
| Kaiser Permanente | Covered for T2D within Kaiser formulary | Internal PA process; lab work and clinical documentation expected |
| Anthem | Covered for diabetes | PA required; diagnosis documentation needed |
| UnitedHealthcare / OptumRx | Available for T2D; listed on OptumRx formulary | PA and quantity limits; step therapy may apply |
According to a GoodRx analysis reported by NPR in April 2026, approximately 12 million commercially insured people lost coverage for Wegovy and 12 million lost coverage for Zepbound between 2025 and 2026, as plans tightened GLP-1 coverage for weight management. Ozempic coverage for diabetes indications has been more stable but plans are increasingly scrutinizing off-label prescribing.
The Medicare GLP-1 Bridge (July 2026)
On May 7, 2026, CMS announced the Medicare GLP-1 Bridge, a temporary program running from July 1, 2026 through December 31, 2027. The program provides eligible Medicare Part D beneficiaries access to GLP-1 medications approved for weight management — specifically Wegovy, Zepbound (KwikPen), and Foundayo — for a $50 monthly copay. Ozempic is not an eligible drug under the Bridge because it is not approved for weight management. Ozempic remains available to Medicare beneficiaries through standard Part D coverage for its FDA-approved diabetes and cardiovascular/kidney indications.
Eligibility criteria for the Bridge program require a diagnosis of obesity or overweight with qualifying conditions (such as heart failure, chronic kidney disease, prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease). Not all Medicare beneficiaries will qualify. Coverage requires a provider prescription, prior authorization, and CMS eligibility verification.
What to monitor
- IRA price negotiation: Ozempic and Wegovy (semaglutide) were selected in January 2025 for the second round of Medicare drug price negotiations. Negotiated prices would take effect in 2027 and could significantly reduce Part D costs.
- List price reduction: In February 2026, Novo Nordisk announced a significant reduction in the US list price for Wegovy, Ozempic, and Rybelsus, effective January 1, 2027.
- Medicare GLP-1 Bridge rollout: Monitor CMS guidance on the July 2026 launch, eligible populations, and participating Part D plans.
- Formulary shifts: Some commercial plans are tightening GLP-1 PA criteria or moving GLP-1s to higher tiers for 2026. Monitor plan formulary updates during open enrollment.
Sources
- FDA, Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
- FDA, Ozempic approval for kidney disease and CV death risk reduction: https://www.fda.gov/drugs/nda-and-bla-approvals/ozempic-semaglutide-injection
- PrescriberPoint, Ozempic coverage and savings data: https://prescriberpoint.com/therapies/ozempic-adec4fd
- Novo Nordisk, Ozempic cost and savings: https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
- Novo Nordisk, Patient Assistance Program 2026 eligibility: https://www.novocare.com/diabetes/help-with-costs/pap.html
- PMC, Coverage and PA trends for GLP-1 therapies: https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888/
- KFF, Wegovy Medicare coverage analysis: https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
- Novo Nordisk / PR Newswire, Medicare GLP-1 Bridge announcement (May 7, 2026): https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html
- CMS, Medicare GLP-1 Bridge eligible drugs: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- NPR, Patients struggle to pay for obesity drugs as insurance coverage slips (April 2026): https://www.npr.org/2026/04/22/nx-s1-5794613/health-insurance-wegovy-zepbound
